FDA proposes guidance for biosimilar product labels
In proposed draft guidance issued on March 29, FDA is filling out more of the details about how biosimilars will be regulated; in this case, how product labels and medication […]
In proposed draft guidance issued on March 29, FDA is filling out more of the details about how biosimilars will be regulated; in this case, how product labels and medication […]
The IMS Institute for Healthcare Informatics has looked at how the biosimilars market is evolving, finding that there will be substantial savings to payers in the 2016-2020 time frame. However, […]
Imprimis Pharmaceuticals (San Diego) provided its FY2015 financial data on March 23, announcing a 500% increase in revenue—but, at $9.7 million for the full year, its total revenue is barely […]